Multidrug Resistance in Bacteria: A Serious Patient Safety Challenge for India

Purva Mathur, Sarman Singh

Department of Laboratory Medicine, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India

Address for correspondence: Dr. Purva Mathur, E-mail: purvamathur@yahoo.co.in

ABSTRACT

Patient safety is an important issue affecting the delivery of healthcare in developed, transitional and developing countries. With the advancements in patient care, hitherto unknown issues relating to patient safety are emerging. An important problem endangering patient safety is infections acquired in the health care facilities. Health care associated infections (HCAIs) are no longer a local or regional problem. With the dissemination of multi-drug resistant bacteria across the globe, the problem of HCAIs has become even grimmer. The emergence of pan-resistant bacterial strains, compounded by lack of availability of new antimicrobials foretells a grave future for management of infections acquired in hospitals. Therefore, it is important to frame local policies and measures and take affirmative actions for prevention of HCAIs and reduce the burden of multi drug resistance.

Key words: Beta-lactamases, multidrug resistance, methicillin resistant staphylococcus aureus, patient safety, vancomycin resistant enterococcus

INTRODUCTION

Patient safety is an important issue affecting the delivery of healthcare in developed, transitional, and developing countries. With the advancements in patient care, hitherto unknown issues relating to patient safety are emerging. Improvement in patient safety will in the long-term improve the quality of healthcare.2,3 During the past few years, patient safety is being increasingly recognized as an issue of global importance, which is mobilizing increasing attention and actions for improvement.3,4 The main reasons for these developments are the increasing public awareness; increasing role of media in disseminating healthcare related information; and the increasing focus on accountability of healthcare facilities (HCFs). Therefore, the 55th World Health Assembly in 2002 adopted a resolution urging nations to focus attention on patient safety and strengthen safety and monitoring systems.1,2,3

An important problem endangering patient safety is infections acquired in the HCFs. Healthcare associated infections (HCAIs) are no longer a local or regional problem. The implications of HCAIs are enormous in terms of mortality, morbidity, disability, psychosocial effects on society, and the cost of healthcare. With the dissemination of multidrug resistant (MDR) bacteria across the globe, the problem of HCAIs has become even grimmer. Therefore, it is important to frame local policies and measures and take affirmative actions for prevention of HCAIs and reduce the burden of MDR.

That HCAIs are a global patient safety issue is exemplified by the monumental decision taken by the World Alliance for Patient Safety to choose HCAIs as the topic of the first global patient safety challenge.6-8 Leading experts in various fields of Infection Prevention and Patient Safety have joined hands with a common motto of “Clean Care is Safer Care” (CGSC). The activities promoted by this Alliance have stimulated country-level activities to enhance patient safety throughout the world.6-8
As developments during the subsequent years have shown, this decision has catalyzed a chain of interventions in most of the countries, which had previously been without any vision or direction on infection control. A positive outcome of these measures is the reported improvements in hand hygiene in many hospitals across the globe.

**MULTI-DRUG-RESISTANCE IN BACTERIA**

The emergence of pan-resistant bacterial strains, compounded by lack of availability of new antimicrobials foretells a grave future for management of infections acquired in hospitals. This may necessitate a “back to basics” approach of infection control, since simple maneuvers like hand hygiene have been found to reduce cross-transmission of resistant microbes. The major resistant pathogens in HCFs today are methicillin resistant *Staphylococcus aureus* (MRSA), vancomycin resistant Enterococcus (VRE), and extended spectrum β-lactamase (ESBL) producing *Klebsiella pneumoniae* and *Escherichia coli* or pan-drug resistant Gram negative bacteria like *Acinetobacter baumannii* and *Pseudomonas aeruginosa*.\(^{[9-11]}\) *Stenotrophomonas maltophilia* and *Burkholderia cepacia* are also gaining increasing importance due to their intrinsic resistance to antimicrobials.\(^{[9]}\) Currently, as high as 60% of hospital acquired infections (HAIs) may involve antibiotic resistant bacteria.\(^{[9,12-14]}\) They are associated with a higher infection-related costs, longer duration of hospital stay, and higher mortality. The estimated annual costs related to antibiotic resistance range from 100 million $ to 30 billion $ in US hospitals alone.\(^{[12]}\) The alarming scenario of pan-resistant microbial infections is amongst the most critical problems faced by physicians today and a major global public health concern.

The evolution of antimicrobial resistant bacteria stems from a multitude of factors, the most important being the widespread and inappropriate use of antimicrobials and their extensive use as growth enhancers in animal feeds. These pathogens easily cross geographic barriers, highlighting the close ecological niche which humans share with them.\(^{[15-18]}\) Another factor is the growing emphasis on outpatient medical management, which has increased the severity of illness of those who are admitted to the hospitals. Patients with advanced malignancies, organ transplantation, multiorgan failure, or HIV infection are severely immunocompromised and constitute a larger portion of hospital patients now than in the past. These patients are often colonized or infected with unusual and resistant opportunistic organisms. They are also more likely to be treated with procedures (e.g., bone marrow transplantation) and devices (e.g., urinary and central venous catheters) that increase the risk of acquisition of infections.\(^{[19]}\)

Apart from the therapeutic challenge posed by multiresistant pathogens in hospitals, they are now gradually infiltrating into the community, as the patient is discharged from the facility and carries resistant pathogen with him. On the other hand, increased treatment of patients in the community can lead to de novo generation of resistance in the community that is introduced to the hospital by patients on admission. Readmission of patients colonized with resistant organisms represents a hidden reservoir that also needs monitoring and control.\(^{[19]}\) It is likely, given the trend toward greater outpatient care, that prevention and control of antimicrobial resistance will be as important in the outpatient arena as in the inpatient setting.

**PREVENTION OF SPREAD OF INFECTIONS DUE TO MDR PATHOGENS**

The rapid spread of resistant pathogens across boundaries only certifies the fact that the emergence of resistance in one organism in any part of the world, even in animal population may have long-term implications for human health globally. Thus, tackling the menace of antimicrobial resistance is a community responsibility, within and outside the hospital.\(^{[19]}\) The patient related factors for development of HCAIs caused by MDR pathogens like age, underlying illnesses, severity of illness, type of surgeries, etc., are difficult to modify. Thus, basic infection control protocols of hand hygiene, barrier precautions, screening, cohort nursing, environmental cleaning, and judicious antibiotic use are the most effective measures to control the dissemination of multiresistant pathogens in HCFs.

The measures to control the spread of antimicrobial resistance in HCFs are:

- Administrative support
- Standard precautions and contact precautions
- Institution of Stringent Hand Hygiene programs at local, regional, and national levels
- Continuous training of staff at peripheral health centers (PHCs) on basic methods of antimicrobial susceptibility; provision of adequate laboratory reagents, media, and chemicals and equipment to these centers for accurate performance of tests
- Continuous training of healthcare workers in remote areas and PHCs to restrict usage of antimicrobials
- Education of staff of all cadres on hospital infection control practices in all HCFs
• Cohorting of patients in hospitals
• Good clinical practices
• Implementation of preventive bundles for device-associated infections
• Accurate and prompt diagnosis of infectious etiologies
• Judicious use of antimicrobials and formulary restriction
• Regulations to prevent over-the-counter sale of antimicrobials
• Use of pharmacodynamics/pharmacokinetic data for deciding antimicrobial treatment regimens
• De-escalation of antimicrobial treatment for infections like ventilator-associated pneumonia (VAP), urinary tract infection (UTI), etc.
• High dose, short course treatment regimens
• Implementation of strict perioperative antimicrobial prophylactic guidelines
• Formulation and implementation of prophylactic antimicrobial prescription policies by every institution.
• Establishment of pharmacies (at least in larger Indian Hospitals)
• Involvement of clinical microbiology laboratory and prompt communication within an healthcare center
• Proper sterilization and disinfection practices
• Stringent environmental cleaning
• Establishment of few state-of-the-art laboratories in our country for characterization of molecular means for detection of resistance and epidemiological tracing; networking of laboratories
• Continuous research and development for alternative antimicrobials, preventive methods of infections, and environment/ecofriendly techniques.

In essence, antimicrobials cannot cover for faulty practices and improper cleaning and decontamination.

**SCENARIO OF MULTI-DRUG RESISTANCE IN INDIA**

In India, ESBL producing strains of *Enterobacteriaceae* have emerged as a challenge in hospitalized as well as community-based patients. A study conducted at New Delhi in 2002 found 68% of Gram negative bacteria to be ESBL producers, in which 80% of *Klebsiella* were ESBL producers. ESBLs have been reported from community isolates from north India as well. Studies from Coimbatore and Nagpur have shown the prevalence of ESBL to be 40-50% in urinary isolates. A study from Karnataka showed the frequency of ESBLs in neonatal septicemic cases to be 22.7%. A similar study from Lucknow showed high levels of ESBL production (63.6-86.6%).

Metallo-beta-lactamase production is a significant problem especially in hospital isolates of *P. aeruginosa* and *Acinetobacter* sp. In a study conducted at New Delhi in 2005, of the 2,626 strains of Gram negative bacteria, carbapenem resistance was seen in 22%. The Indian Antimicrobial Resistance Study Group has recently published their findings on broad-spectrum beta-lactam resistance and ESBL phenotypes in *Enterobacteriaceae* including *Salmonella* sp. The isolates were part of the MYSTIC Program and consisted of nonduplicate samples from ten different Indian sites in six cities (New Delhi, Mumbai, Indore, Lucknow, Bangalore, and Vellore). From initial phenotypic screening, 92% *E. coli* and 96% *Klebsiella* sp. were confirmed as being ESBL producers. The latest report from National Institute of Communicable Diseases (NICD), New Delhi, India, shows a rise in resistance to cefepime.

In recent studies conducted on Gram positive and Gram negative bacteria from obstetric cases in different parts of our country, a high level of resistance was noted to beta-lactams, fluoroquinolones, and cotrimoxazole. This finding is significant in view of the fact that most of the pathogens would be community acquired. The Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India, in a study conducted at 15 tertiary care centers on 26,310 isolates of *S. aureus* found the prevalence of MRSA to be 41%. A high rate of resistance to ciprofloxacin, gentamycin, cotrimoxazole, erythromycin, and clindamycin was also seen in MRSA. In comparison, the rates of VRE are slightly lower.

**PATIENT SAFETY**

Patient safety is the absence of preventable harm to a patient during the process of healthcare. The discipline of patient safety deals with the coordinated efforts to prevent harm, caused by the process of healthcare itself, from occurring to patients.

**GLOBAL SAFETY CHALLENGES**

The World Alliance for Patient Safety identifies specific areas for action which address significant risk to patient safety, relevant to all countries. Thus, the World Alliance selects a new and important global patient safety issue and establishes a program to tackle this. It devices modules and guidelines to stimulate country-level actions on this issue. These programs are called the Global Patient Safety...
Mathur and Singh: Infections by multidrug resistant bacteria pose a serious threat to patient safety

Challenge (GPSC). The topic of the challenge is selected every 2 years, based on a significant risk to patients in every World Health Organization (WHO) member state. The WHO has been entrusted with the task of framing global norms and standards and supporting country efforts in developing patient safety policies and practices.

In view of the increasing burden of HCAIs in developed, transitional, and developing countries; the topic for the first global patient safety challenge has been very appropriately chosen as HCAIs. This challenge focuses on creating awareness and reducing the burden of HCAIs as a vital element of patient safety. The theme of this challenge, promulgated for 2005-2006 was “Clean Care is Safer Care” (CGiSC). A key objective of the program was to launch a feasible and practical approach to improve hand hygiene in healthcare globally.\[1,2,5,33\]

With the slogan of CGiSC, the first global challenge aims at implementing several actions to reduce HCAI worldwide, irrespective of the level of development of a country or its healthcare systems and the availability of resources. The four major objectives of the first challenge were: Awareness raising about the problem and impact of HCAI on patient safety; building commitment from countries, that is, motivating Country Pledges to tackle HCAIs as a priority; to draft recommendations based on scientific evidence to promote hand hygiene in health set-ups; and to field test the implementations of the new WHO Guidelines on Hand Hygiene in Health Care.\[1,2,5,32,33\]

The ultimate objective of all these actions is to enable acceptance of hand hygiene as a basic healthcare activity or a fundamental procedure during delivery of healthcare which will reduce the risk of infection. Thus, the first challenge envisages the institutionalization of hand hygiene in each member country, with the help of the WHO guidelines.

HAND HYGIENE AS THE FOUNDATION OF CLEAN CARE IS SAFER CARE

Since hand hygiene has been proven to reduce infections in HCFs, a major action within the global challenge is to promote its implementation in healthcare segments globally as well as at country level. In order to provide healthcare workers, hospital administrators, and health authorities with the best scientific evidence and recommendations to improve practices and reduce HCAIs; the WHO had developed new guidelines on Hand Hygiene in Health Care (advance draft). Thus, one of the major actions to improve patient safety within CGiSC is to advance hand hygiene as the basic foundation of infection prevention.\[6,33-36\]

Towards this end, an international awareness raising campaign has been initiated, focusing primarily on hand hygiene. Such campaigns would promote political and administrative support and action. The following actions have been strategized to implement universal hand hygiene: System change; availability of alcohol-based hand rubs at point of care; access to soap and clean running water; training and education; monitoring and evaluation; reminders in the work place; and institutional safety climate, including patient partnership activity.

TACKLING ANTIMICROBIAL RESISTANCE: THE THIRD GLOBAL PATIENT SAFETY CHALLENGE

In 2008, the World Alliance for Patient Safety announced its 3rd Global Patient Safety Challenge: Tackling Antimicrobial Resistance. The work builds upon previous works of the WHO, particularly the Global Strategy for Containment of Antimicrobial Resistance published in 2001. The new project, under the leadership of David Heymann and Didier Pittet, is facilitating an international coalition to address the threat to patient safety posed by antimicrobial resistance. At a first international consultation in July 2008, at WHO headquarters in Geneva, it was agreed that the 3rd Patient Safety Challenge will concentrate on five key action areas:37

• Animal husbandry, aquaculture, and agriculture; including the examination of the regulation of antimicrobial use in food production processes.
• Infection control including the promotion of simple and effective interventions to reduce transmission of resistant microbes in both hospital and community settings.
• Rational drug use and regulation including access, quality, and misuse of antimicrobial agents.
• Research and development of efficient and affordable diagnostic methods to support rapid, targeted treatment, and new antimicrobial agents including vaccines and alternative therapies.
• Surveillance including developing laboratory capacity and the development of a long-term strategy to collect and report high quality data in a systematic fashion.

The work is being undertaken in two stages. During the initial ‘foundation’ period in 2008 and 2009, five expert working groups met to formulate a WHO Global Work Plan for Antimicrobial Resistance. In 2010, WHO launched the ‘challenge’ component, encouraging all member states to sign up to an intervention, or a focused bundle of interventions, to reduce the threat of resistance.
On 8 March, 2012, WHO launched a new book “The evolving threat of antimicrobial resistance-Options for action”. It examines the experiences with interventions which address the growing threat of antimicrobial resistance, describes the lessons learnt along the way and highlights the gaps still remaining. It draws attention to areas where knowledge is lacking and where urgent action is still needed.

It is hoped that formulation and implementation of these challenges will truly catalyze actions towards reduction of HCAIs and antimicrobial resistance, thereby benefitting the patients and the healthcare community at large.

Where does India stand with respect to patient safety?

India was the first SEARO country to pledge support to the CGIsc campaign. This was done on 14th June, 2006. As part of the 1-day meeting, a technical session on infection prevention was held with participation from various experts.[38]

Road ahead

It is now time that implementable policies and affirmative actions are taken to prevent the dissemination of MDR pathogens in Indian hospitals; stop the rampant misuse of antimicrobials; and ultimately, provide an environment of patient safety in all types of HCFs of our country.

REFERENCES

1. Pittet D, Allegranzi B, Storr J, Donaldson L. Clean care is Safer Care: The global patient safety challenge 2005-2006. Int J Infect Dis 2006;10:419-24.
2. Pittet D, Donaldson L. Clean care is safer care: The first global challenge of the WHO World Alliance for Patient Safety. Am J Infect Control 2005;33:476-9.
3. Wilson RM, Runciman WB, Gibbert RW, Harrison BT, Newby L, Hamilton JD. The quality in Australian Health Care study. Med J Aust 1995;163:458-71.
4. Schoiier T, Lipetzak H, Pedersen BL, Mogensen TS, Bech KB, Stockmarr A, et al. Danish Adverse Event Study. Incidence of adverse events in hospitals. A retrospective study of medical records. Ugeskr Laeger 2001;163:5370-8. 5. Pittet D, Donaldson L. Challenging the world: Patient safety and health care associated infection. Int J Qual Health Care 2005;18:4-8.
6. World Alliance for patient safety global patient safety challenge 2005-2006: Clean care is safer care. Geneva: World Health Organization, 2005. Available from: http://www.who.int/patientsafety/events/05/gpse_Launch_ENGLISH_FINAL.pdf [Last accessed on 2013 May 3].
7. Patient safety. Available from: http://www.who.int/patientsafety/about/en/index.html [Last accessed on 2013 May 3].
8. World Alliance for patient safety Forward programme 2005. Geneva: World Health Organization, 2004. Available from: http://www.who.int/patientsafety/en/brochure_final.pdf [Last accessed on 2012 Aug 12].
9. Siegel JD, Rhinehart E, Jackson M, Chiarello L. The Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007;35:165-93.
10. Slama TG. Gram-negative antibiotic resistance: There is a price to pay. Crit Care 2008;12(Suppl 4):S4.
11. Falagas ME, Bliziotis IA. Pan drug resistant gram negative bacteria: The dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29:630-6.
12. Haddadin AS, Fappiano SA, Lipsatt PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002;78:385-92.
13. Nicolle LE. Infection control programmes to contain antimicrobial resistance. WHO/CDS/CSR/DRS/2001.7.
14. Croft AC, D’Anthoni AV, Terzulli SL. Update on the antibacterial resistance crisis. Med Sci Monit 2007;13:RA103-18.
15. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003;111:1265-73.
16. Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992;257:1050-5.
17. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. N Engl J Med 1994;330:1247-51.
18. Swartz MN. Use of antimicrobial agents and drug resistance. N Engl J Med 1997;337:491-2.
19. Shales DM, Genling BN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for healthcare epidemiology of America and infections. Diseases society of America joint Committee on the prevention of antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275-91.
20. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing Gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-7.
21. Babypadmini S, Appalaraju B. Extended spectrum beta lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae-prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004;22:172-4.
22. Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004;120:553-6.
23. Vinodkumar CS, Ncelagund YF. Emergence of extended spectrum beta lactamase mediated resistance in neonatal septicemia. Indian J Pathol Microbiol 2006;49:616-9.
24. Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended spectrum beta-lactamase-producing Gram negative bacteria in septicaeonic neonates in a tertiary care hospital. J Med Microbiol 2003;52:421-5.
25. Hemlatha V, Sekar U, Kamat V. Detection of metallobetalactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res 2005;122:148-52.
26. Jones RN, Rhomberg PR, Varnam DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: Initial studies for the MYSTIC program in India. Int J Antimicrob Agents 2002;20:426-31.
27. Grover SS, Sharma M, Chattopadhyay D, Kapoor H, Pasha ST, Singh G. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: Emergence of high resistance against cepfepime, the fourth generation cephalosporin. J Infect 2006;53:279-88.
28. Sabharwal ER. Antibiotic susceptibility patterns of uropathogens in obstetric patients. N Am J Med Sci 2012;4:316-9.
29. Pathak A, Chandran SP, Mahalak K, Macaden R, Lundborg CS. Frequency and factors associated with carriage of multi-drug resistant commensal Escherichia coli among women attending antenatal clinics in Central India. BMC Infect Dis 2013;13:199.
30. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India. Methicillin resistant Staphylococcus aureus (MRSA) in India: Prevalence and susceptibility pattern. Indian J Med Res 2013;137:363-9.
31. Fernandes SC, Dhanashree B. Drug resistance and virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res 2013;137:981-5.
32. Patient Safety Challenge. Available from: http://www.who.int/patientsafety/challenge/en [Last accessed on 2013 May 3].
33. Allegranzi B, Storr J, Djizcan G, Leotsakos A, Donaldson L, Pittet D. The first global patient safety challenge “clean care is safer care”;
Mathur and Singh: Infections by multidrug resistant bacteria pose a serious threat to patient safety

From launch to current progress and achievements. J Hosp Infect 2007;65:115-23.
34. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneu S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000;356:1307-12.
35. Allegranzi B, Sax H, Bengaly I, Richet H, Minta DK, Chraiti MN, et al. World Health Organization “Point G” Project Management Committee. Successful implementation of the World Health Organization H and Hygiene improvement strategy in a referral hospital in Mali, Africa. Infect Control Hosp Epidemiol 2010;31:133-41.
36. Sax H, Allegranzi B, Uckay I, Larson E, Boyce J, Pittet D. ‘My five moments for hand hygiene’: A user centered design approach to understand, train, monitor and report hand hygiene. J Hosp Infect 2007;67:9-21.
37. Available from: http://www.cgdev.org/content/article/detail/14 [Last accessed on 2013 May 3].
38. Clean hands net. Available from: http://www.who.int/gpsc/national_campaign/[Last accessed on 2013 May 3].

How to cite this article: Mathur P, Singh S. Multidrug resistance in bacteria: A serious patient safety challenge for India. J Lab Physicians 2013;5:5-10.

Source of Support: Nil. Conflict of Interest: None declared.

Author Help: Online submission of the manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:
 Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article File:
 The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1024 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) Images:
 Submit good quality color images. Each image should be less than 4096 kb (4 MB) in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:
 Legends for the figures/images should be included at the end of the article file.